by Matthew Johnson | Oct 27, 2017 | 325(d) issues, Trial Institution
By Rich Graham and Matt Johnson On October 24th, the PTAB designated three decisions related to discretionary petition denials under 35 U.S.C. § 325(d) as informative. Unified Patents, Inc. v. Berman is discussed below. We previously reported on Hospira, Inc. v....
by Cary Miller | Oct 3, 2017 | Trial Institution
By Lin Yu, Ph.D. and Cary Miller, Ph.D. In IPR2017-01054 and IPR2017-01055 (Fresenius Kabi USA, LLC v. Hospira Inc.), the PTAB denied institution of inter partes reviews of U.S. Patent Nos. 8,242,158 and 8,338,470, because Petitioner Fresenius filed the IPR petitions...
by Carl Kukkonen | Oct 2, 2017 | Claim Construction, Trial Institution
By Carl Kukkonen and Amanda Leckman On September 13, 2017, the PTAB, a five-judge panel, granted a petition to institute an inter partes review brought by HTC America, Inc. (“Petitioner”) against Virginia Innovation Sciences, Inc. (“Patent Owner”) regarding U.S....
by Joe Sauer | Aug 24, 2017 | Federal Circuit, Trial Institution
By Joseph M. Sauer The Federal Circuit’s decision in Nidec Motor Corp. v. Zhongshan Broad Ocean Motor Co., (Fed. Cir. No. 16-2321), expresses a growing discomfort with the Patent Office’s practice of joinder and expanded panels. Procedural History The procedural...
by Cary Miller | Aug 9, 2017 | Pharmaceutical, Trial Institution
By Raffaella Faraoni, Ph.D. and Cary Miller, Ph.D. At least 19 IPRs have been filed against seven of Genentech’s patents covering its blockbuster antibody drug Herceptin® (trastuzumab). On July 27, 2017, the PTAB instituted IPRs filed by Hospira, Inc. (a subsidiary of...
by Cary Miller | Jul 20, 2017 | Pharmaceutical, Trial Institution
By Achim Brinker, Ph.D. and Cary Miller, Ph.D. In orders entered July 10 and 12, 2017, the PTAB instituted further inter partes review (IPR) of six Allergan Inc. (“Allergan”) patents relating to cyclosporine compositions. Each of U.S. Patent Nos. 8,633,162,...
